Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Ultraviolet radiation drives mutations in a subset of mucosal melanomas

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Hepatitis C virus envelope protein dynamics and the link to hypervariable region 1

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • STOP-HCV Consortium
Vis graf over relationer

Persistent hepatitis C virus (HCV) infection is a major cause of chronic liver disease, worldwide. With the development of direct-acting antivirals, treatment of chronically infected patients has become highly effective, although a subset of patients responds less well to therapy. Sofosbuvir is a common component of current de novo or salvage combination therapies, that targets the HCV NS5B polymerase. We use pre-treatment whole-genome sequences of HCV from 507 patients infected with HCV subtype 3a and treated with sofosbuvir containing regimens to detect viral polymorphisms associated with response to treatment. We find three common polymorphisms in non-targeted HCV NS2 and NS3 proteins are associated with reduced treatment response. These polymorphisms are enriched in post-treatment HCV sequences of patients unresponsive to treatment. They are also associated with lower reductions in viral load in the first week of therapy. Using in vitro short-term dose-response assays, these polymorphisms do not cause any reduction in sofosbuvir potency, suggesting an indirect mechanism of action in decreasing sofosbuvir efficacy. The identification of polymorphisms in NS2 and NS3 proteins associated with poor treatment outcomes emphasises the value of systematic genome-wide analyses of viruses in uncovering clinically relevant polymorphisms that impact treatment.

OriginalsprogEngelsk
Artikelnummer6105
TidsskriftNature Communications
Vol/bind12
Udgave nummer1
ISSN2041-1723
DOI
StatusUdgivet - 20 okt. 2021

Bibliografisk note

© 2021. The Author(s).

ID: 68558504